: Citigroup: MEDBOT-B (02252) revenue growth exceeded expectations last year, standardized fee policies considered industry milestone.

Citibank released a research report stating that MEDBOT-B (02252) has announced a strong positive profit forecast for the fiscal year 2025, indicating a year-on-year revenue growth of 110% to 120%, surpassing the bank's expectation of 100% increase and the market's expectation of 94% increase. The bank believes that the revenue exceeding expectations is a key highlight, confirming that the company is in a phase of rapid global business expansion, and revenue growth is the most critical indicator for investors. Citibank gave a "buy" rating to Weichai Siasun Robot & Automation, with a target price of 32 Hong Kong dollars. The report mentioned that this momentum is mainly driven by Weichai Siasun Robot & Automation's overseas orders for the fiscal year 2025 exceeding 100 units, surpassing the guidance of 70 to 80 units given in August, providing excellent visibility for revenue conversion in fiscal year 2026. The market reacted positively to the new "Guidelines for the Pricing of Pathology Medical Services Projects (Trial)" released by the government on January 21, causing the stock prices of Weichai Siasun Robot & Automation and its industry peers to rise. The bank views this policy as a milestone, as it reduces the risk of the commercialization path and provides a clear and unified framework for industry growth.